Federal Register / Vol. 70, No. 213 / Friday, November 4, 2005 / Notices 67179 

SUPPLEMENTARY INFORMATION: In FR Doc. 

03–4691, appearing on page 9690 in the 

Federal Register of February 28, 2003, 

the following corrections are made: 

1. On page 9690, in the third column, 

in the first complete paragraph, in the 

third line, ‘‘2,810’’ is corrected to read 

‘‘2,901’’; in the fourth line, ‘‘2,201’’ is 

corrected to read ‘‘2,292’’. 

2. On page 9690, in the third column, 

in the second complete paragraph, 

beginning in the fourth line, ‘‘December 

12, 1993’’ is corrected to read 

‘‘September 12, 1993’’; in line 10, 

‘‘December 12, 1993’’ is corrected to 

read ‘‘September 12, 1993’’. 

Dated: October 20, 2005. 

Jane A. Axelrad, 

Associate Director for Policy, Center for Drug 

Evaluation and Research. 

[FR Doc. 05–22012 Filed 11–3–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Pediatric Advisory Committee; Notice 

of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Pediatric 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. The committee 

also advises and makes 

recommendations to the Secretary under 

45 CFR 46.407 on research involving 

children as subjects that is conducted or 

supported by the Department of Health 

and Human Services, when that 

research is also regulated by FDA. 

Date and Time: The meeting will be 

held on Friday, November 18, 2005, 

from 8 a.m. to 2 p.m. 

Location: Washington DC North/ 

Gaithersburg Hilton, 620 Perry Pkwy., 

Gaithersburg, MD. 

Contact Person: Jan N. Johannessen, 

Office of Science and Health 

Coordination of the Office of the 

Commissioner (HF–33), Food and Drug 

Administration, 5600 Fishers Lane (for 

express delivery, rm. 14C–06), 

Rockville, MD 20857, 301–827–6687, or 

by e-mail: jjohannessen@fda.gov or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

8732310001. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: The committee will discuss a 

report by the agency on Adverse Event 

Reporting, as mandated in Section 17 of 

the Best Pharmaceuticals for Children 

Act, for AGRYLIN (anagrelide), 

PARAPLATIN (carboplatin), DIFLUCAN 

(fluconazole), CAMPTOSAR 

(irinotecan), TAMIFLU (oseltamivir), 

VIOXX (rofecoxib), FERRLECIT (sodium 

ferric gluconate complex), and IMITREX 

(sumatriptan). 

The background material will become 

available no later than the day before 

the meeting and will be posted under 

the Pediatric Advisory Committee 

Docket site at http://www.fda.gov/ 

ohrms/dockets/ac/acmenu.htm. (Click 

on the year 2005 and scroll down to 

Pediatric Advisory Committee 

meetings.) 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person by November 10, 2005. Oral 

presentations from the public will be 

scheduled on Friday, November 18, 

2005, between approximately 8:30 a.m. 

and 9:30 a.m. Time allotted for each 

presentation may be limited. Those 

desiring to make formal oral 

presentations should notify the contact 

person by November 10, 2005, and 

submit a brief statement of the general 

nature of the evidence or arguments 

they wish to present, the names and 

addresses of proposed participants, and 

an indication of the approximate time 

requested to make their presentation. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Jan 

Johannessen at least 7 days in advance 

of the meeting. 

Notice of this meeting is given under 

the Federal Advisory Committee Act (5 

U.S.C. app. 2). 

Dated: October 31, 2005. 

Jason Brodsky, 

Acting Associate Commissioner for External 

Relations. 

[FR Doc. 05–22014 Filed 11–3–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

Advisory Committee on Special 

Studies Relating to the Possible LongTerm Health Effects of Phenoxy 

Herbicides and Contaminants (Ranch 

Hand Advisory Committee); Notice of 

Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Advisory 

Committee on Special Studies Relating 

to the Possible Long-Term Health Effects 

of Phenoxy Herbicides and 

Contaminants (Ranch Hand Advisory 

Committee). 

General Function of the Committee: 

To advise the Secretary of Health and 

Human Services (the Secretary) and the 

Assistant Secretary for Health 

concerning its oversight of the conduct 

of the Ranch Hand study by the U.S. Air 

Force and provide scientific oversight of 

the Department of Veterans Affairs 

Army Chemical Corps Vietnam Veterans 

Health Study, and other studies in 

which the Secretary or the Assistant 

Secretary for Health believes 

involvement by the committee is 

desirable. 

Date and Time: The meeting will be 

held on November 18, 2005, from 8:30 

a.m. to 4 p.m. 

Location: Food and Drug 

Administration, 5630 Fishers Lane, rm. 

1066, Rockville, MD 20857. 

Contact Person: Leonard Schechtman, 

National Center for Toxicological 

Research (HFT–10), Food and Drug 

Administration, 5600 Fishers Lane, 

Rockville, MD 20857, 301–827–6696, or 

FDA Advisory Committee Information 

Line, 1–800–741–8138 (301–443–0572 

in the Washington, DC area), code 

3014512560. Please call the Information 

Line for up-to-date information on this 

meeting. 

Agenda: The committee will discuss 

the following items: (1) Updates and 

interactions with the Institute of 

Medicine’s Air Force Health Study 

(AFHS) Disposition Study Committee; 

(2) AFHS closure preparations; (3) 

updates from the Air Force on the AFHS 

history, program management, and the 

Comprehensive Study Report; (4) 

67180 Federal Register / Vol. 70, No. 213 / Friday, November 4, 2005 / Notices 

update from the Air Force on the 2002 

AFHS Physical Examination Report; and 

(5) discussion of AFHS fiscal year 2006 

activities. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person by November 10, 2005. Oral 

presentations from the public will be 

scheduled on November 18, 2005, 

between approximately 11:15 a.m. to 

12:15 p.m. Time allotted for each 

presentation may be limited. Those 

desiring to make formal oral 

presentations should likewise notify the 

contact person before November 10, 

2005, and submit a brief statement of 

the general nature of the evidence or 

arguments they wish to present, the 

names and addresses of proposed 

participants, and an indication of the 

approximate time requested to make 

their presentation. 

Persons attending FDA’s advisory 

committee meetings are advised that the 

agency is not responsible for providing 

access to electrical outlets. 

FDA welcomes the attendance of the 

public at its advisory committee 

meetings and will make every effort to 

accommodate persons with physical 

disabilities or special needs. If you 

require special accommodations due to 

a disability, please contact Leonard 

Schechtman at least 7 days in advance 

of the meeting. 

Dated: October 28, 2005. 

Jason Brodsky, 

Acting Associate Commissioner for External 

Relations. 

[FR Doc. 05–22013 Filed 11–3–05; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel, 

Information Resources for Radiation Science. 

Date: December 8, 2005. 

Time: 1 p.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6130 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Timothy C. Meeker, MD, 

Scientific Review Administrator, Special 

Referral and Resources Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Boulevard, Room 

8088, Rockville, MD 20852, 301/594–1279. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support, 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: October 28, 2005. 

Anthony M. Coelho, Jr., PhD. 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–21999 Filed 11–3–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meetings 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Cancer Institute Director’s 

Consumer Liaison Group. 

The meetings will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Director’s Consumer Liaison Group. 

Date: December 1, 2005. 

Time: 2 p.m. to 3 p.m. 

Agenda: 1. NCI Listens and Learns Web 

Site; 2. Update on Summit planning; 3. 

Update from OLA; 4. Public Comment; 5. 

Next Steps. 

Place: National Institutes of Health, 6116 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call) 

Contact Person: Brooke Hamilton, 

Executive Secretary, Office of Liaison 

Activities, National Institutes of Health, 

National Cancer Institute, 6116 Executive 

Blvd., Suite 220, MSC 8324, Bethesda, MD 

20891, 301–435–3855, 

hamiltbr@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/dclg/dclg.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: October 28, 2005. 

Anthony M. Coelho, Jr. 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–22000 Filed 11–3–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel, Clinical Trials of 

Silymarin for Liver Diseases. 

Date: December 1, 2005. 

Time: 8 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Double Tree Rockville, 1750 

Rockville Pike, Rockville, MD 20852.